BridgeBio price target raised to $52 from $49 at Scotiabank

Scotiabank raised the firm’s price target on BridgeBio (BBIO) to $52 from $49 and keeps an Outperform rating on the shares. The company’s earnings release reflects “stellar commercial momentum” in the early launch of Attruby in transthyretin amyloid cardiomyopathy, the analyst tells investors. In the firm’s view, the rapid uptake of Attruby is reflective of the robust and broad incentive to prescribe the drug as a first line of defense given its clinical profile.